Enanta Pharmaceuticals, Inc., a biotechnology company, focuses on the research and development of small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, non-alcoholic steatohepatitis, primary biliary cholangitis, and hepatitis B virus. Enanta Pharmaceuticals, Inc. has a collaborative development and license agreement with Abbott Laboratories to identify, develop, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir for the treatment of chronic hepatitis C virus. The company was founded in 1995 and is headquartered in Watertown, Massachusetts.

Receive ENTA News and Ratings via Email

Sign-up to receive the latest news and ratings for ENTA and its competitors with MarketBeat's FREE daily newsletter.

Miscellaneous

Enanta Pharmaceuticals (NASDAQ:ENTA) Frequently Asked Questions

What is Enanta Pharmaceuticals' stock symbol?

Enanta Pharmaceuticals trades on the NASDAQ under the ticker symbol "ENTA."

How were Enanta Pharmaceuticals' earnings last quarter?

Enanta Pharmaceuticals Inc (NASDAQ:ENTA) posted its quarterly earnings data on Wednesday, February, 6th. The biotechnology company reported $1.25 EPS for the quarter, missing the Zacks' consensus estimate of $1.46 by $0.21. The biotechnology company earned $69.89 million during the quarter, compared to the consensus estimate of $71.27 million. Enanta Pharmaceuticals had a net margin of 36.19% and a return on equity of 22.78%. The company's revenue for the quarter was up 83.4% compared to the same quarter last year. During the same period in the prior year, the company posted $0.59 earnings per share. View Enanta Pharmaceuticals' Earnings History.

When is Enanta Pharmaceuticals' next earnings date?

What price target have analysts set for ENTA?

6 Wall Street analysts have issued 1 year price targets for Enanta Pharmaceuticals' stock. Their forecasts range from $80.00 to $133.00. On average, they anticipate Enanta Pharmaceuticals' share price to reach $102.60 in the next year. This suggests a possible upside of 4.7% from the stock's current price. View Analyst Price Targets for Enanta Pharmaceuticals.

What is the consensus analysts' recommendation for Enanta Pharmaceuticals?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Enanta Pharmaceuticals in the last year. There are currently 4 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Enanta Pharmaceuticals.

Has Enanta Pharmaceuticals been receiving favorable news coverage?

News coverage about ENTA stock has been trending somewhat positive this week, according to InfoTrie Sentiment. InfoTrie rates the sentiment of press coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Enanta Pharmaceuticals earned a news impact score of 1.0 on InfoTrie's scale. They also gave news coverage about the biotechnology company a news buzz of 2.0 out of 10, indicating that recent press coverage is very unlikely to have an effect on the company's share price in the near future.

Which major investors are selling Enanta Pharmaceuticals stock?

ENTA stock was sold by a variety of institutional investors in the last quarter, including Prudential Financial Inc., Acadian Asset Management LLC, Great Point Partners LLC, Mackenzie Financial Corp, First Trust Advisors LP, First Manhattan Co., Barclays PLC and BlackRock Inc.. Company insiders that have sold Enanta Pharmaceuticals company stock in the last year include Bruce L A Carter, Jay R Luly, Nathalie Adda, Nathaniel S Gardiner, Paul J Mellett, Tim Ocain and Yat Sun Or. View Insider Buying and Selling for Enanta Pharmaceuticals.

How do I buy shares of Enanta Pharmaceuticals?

Shares of ENTA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Enanta Pharmaceuticals' stock price today?

One share of ENTA stock can currently be purchased for approximately $98.02.

How big of a company is Enanta Pharmaceuticals?

Enanta Pharmaceuticals has a market capitalization of $1.91 billion and generates $206.63 million in revenue each year. The biotechnology company earns $71.95 million in net income (profit) each year or $3.48 on an earnings per share basis. Enanta Pharmaceuticals employs 113 workers across the globe.

MarketBeat Community Rating for Enanta Pharmaceuticals (NASDAQ ENTA)

MarketBeat's community ratings are surveys of what our community members think about Enanta Pharmaceuticals and other stocks. Vote "Outperform" if you believe ENTA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ENTA will underperform the S&P 500 over the long term. You may vote once every thirty days.